Wegovy list price cut arrives in January as the pill lifts Novo sales
Novo Nordisk will drop the US list price of Wegovy, Ozempic and Rybelsus to $675 a month on January 1. Its third quarter shows the pill now drives US Wegovy growth, but what patients pay depends on their plan.
Who feels it
-
Payers
Rethink
Mercer expects smaller rebates to offset the lower list price, so employers may carry a slightly larger share of net cost.
-
Patients
Adjust
People on coinsurance or high deductible plans may pay less from January; flat copay and self-pay prices are not changed by this step.
-
Prescribers
Worth knowing
Expect cost questions in January; out of pocket savings depend on plan design, not the new list price alone.
-
Pharmacies
Worth knowing
List prices on Wegovy, Ozempic and Rybelsus invoices fall from January 1; actual payment depends on your contracts.
-
Sellers
Worth knowing
A lower list price narrows the sticker gap that compounded and telehealth offers point to, but self-pay prices stay as they are.
Novo Nordisk's Wegovy list price cut takes effect on January 1, 2027, when the US list price of Wegovy, Ozempic and Rybelsus falls to $675 a month. The company's third quarter report shows why that date matters: the Wegovy pill now carries US growth while sales of the injection shrink. Management has warned that the lower prices will weigh on cash flow next year. For patients, the real question is who actually pays less, because a list price is rarely what people hand over at the counter.
What changes on January 1
The Wegovy list price cut was announced on February 24, 2026, and starts on the first day of 2027. The new list price, also called the wholesale acquisition cost, will be $675 a month for the Wegovy injection, the Wegovy tablet, Ozempic and Rybelsus, Novo's semaglutide tablet for type 2 diabetes. The company said that is about 50% below the current Wegovy price and about 35% below the current Ozempic list price, and that the change covers every dose. In its February price announcement, Novo also said the move does not touch its direct-to-patient self-pay prices. People who already pay cash through the company's own channels should not expect a new number from this step.
Jamey Millar, who leads US operations at Novo, said the lower list price is aimed at people "whose out-of-pocket costs are linked to list price." He named high-deductible health plans and coinsurance designs, where a patient pays a share of the full price rather than a flat copay. Those people can see the sticker number almost directly in their bill, at least until a deductible is met. Anyone on a fixed copay may notice little change. Novo did not say how many patients fall into those groups. The timing also matches the Medicare maximum fair price, which the benefits consultancy Mercer noted starts on the same January 1 date. The table below sets out the dates and figures that frame the change.
| Date | Event | Reported by |
|---|---|---|
| Feb 24 2026 | Novo announces a $675 monthly US list price for Wegovy, Ozempic and Rybelsus | Novo Nordisk |
| Q3 2026 | US Wegovy injection sales fall 13% at constant exchange rates | Novo Q3 report |
| Q3 2026 | Wegovy pill earns DKK 4.18 billion in the US and DKK 1.22 billion elsewhere | Novo Q3 report |
| Oct 23 2026 | Four week average of weekly pill prescriptions essentially unchanged | Citi, as reported |
| By end of 2026 | FDA decision on CagriSema expected | Novo plans, as reported |
| Jan 1 2027 | New list prices take effect | Novo Nordisk |
Wegovy pill sales carry the quarter
The Novo Nordisk third quarter report shows a split business in the United States. Sales of the Wegovy injection fell 13% at constant exchange rates, while the tablet brought in DKK 4.18 billion in US sales alone. Taken together, US Wegovy sales grew 21%, the report says, the clearest sign yet of the tablet's weight inside the brand. Outside the US, Wegovy pill sales added DKK 1.22 billion and the injection grew 16%. Across all markets the tablet earned about DKK 5.39 billion in the quarter, which ad-hoc-news, citing Reuters, put above an analyst consensus of DKK 4.62 billion. For the first nine months, Novo said falling US injection sales were driven by lower realised prices, partly countered by higher volumes.
Sales of the Wegovy injection fell 13% at constant exchange rates, while the tablet brought in DKK 4.18 billion in US sales alone.
That gap matters for access because it hints at who is starting treatment. According to a BioSpace report on the results, cited by ad-hoc-news, 80% of patients who began oral Wegovy had no prior treatment. If that share holds, the pill is bringing new people into care rather than moving existing patients from one Novo product to another. The nine month figures need care, though. Novo said US pill sales of DKK 9.58 billion for the period include a first quarter boost from stocking wholesalers and telehealth partners before launch, orders that lift early totals without reflecting new patients. Management has also said pill prescriptions flattened recently, which it put down to seasonal patterns, so one strong quarter is not yet a trend.
Who pays less and who may pay more
A Wegovy list price cut does not lower every bill. Most insured patients pay a copay or coinsurance set by their plan, while insurers pay a net price after rebates that drugmakers keep private. Our guide to one pen and its four prices explains why those numbers drift so far apart. Patients with flat copays would see the same charge as before. Mercer expects Novo to offset part of the lower list price by paying smaller rebates. Under that model the gap between list and net price narrows, and money moves between payers rather than disappearing. Mercer said members who pay coinsurance may see lower costs at the pharmacy counter, while employers may pay a slightly larger share of the total.
That shift lands on employers already weighing whether to keep weight loss cover in 2027. Some large companies are dropping it, as we reported in our story on coverage shrinking without savings. For people on Medicare, the negotiated maximum fair price and the separate GLP 1 Bridge copay set their own terms, so the Ozempic list price matters less to what they pay. Novo said the change does not affect its other access efforts, including self-pay prices. What any single plan member pays next year will depend on plan design, deductibles and rebate deals, none of which the announcement addresses. Pharmacies will see a lower list figure on invoices, though what they are paid depends on their own contracts.
What the quarter does not settle
Novo's management has said the cuts will weigh on cash flow next year, according to the ad-hoc-news analysis, while the company still guides to full year free cash flow of DKK 60 to 70 billion. HSBC said Novo's cautious plan implies an 8% fall in fourth quarter adjusted operating profit at constant exchange rates. Analysts also questioned the quality of the quarter. Jefferies said a DKK 2 billion gross-to-net pricing benefit lifted results, and that injectable Wegovy would have missed revenue forecasts without it. Gross-to-net is the gap between the list price and what a company keeps after rebates and discounts, the same gap the January change is meant to shrink. Reuters reported that Novo's guidance assumes US sales fall this year while international sales grow.
Demand signals are mixed. Citi read the four week average of weekly pill prescriptions through October 23 as essentially unchanged. A pause in prescriptions is not proof of a stall, but it limits how far one quarter can be read forward. Rival Eli Lilly faces the same squeeze, and its third quarter showed higher volume at realised prices that fell 15%. Because list prices are not realised prices, the Wegovy list price cut will not remove revenue one for one, and patients will not all see a 50% drop. Another date to watch is the expected FDA decision on CagriSema, Novo's next obesity drug, which the company expects before the end of 2026 with a US launch planned for early 2027 if approved.
Conclusion
The Wegovy list price cut is fixed for January 1, 2027, and Novo Nordisk says it will bring the monthly list price of its semaglutide brands to $675. The third quarter shows the pill now carries US growth as the injection loses sales. Still unknown is how plans pass the cut through, how far rebates shrink and whether employers keep paying. Patients on coinsurance or high deductibles stand to gain most; people on flat copays or cash prices may see no change.
Source Novo Nordisk Q3 2026 report (SEC Form 6-K); Novo Nordisk US press release of Feb 24, 2026; Mercer analysis; ad-hoc-news.de analysis citing Reuters, BioSpace, Jefferies, HSBC and Citi
Sources
- Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic and Rybelsus
- Novo Nordisk A/S Form 6-K, Q3 2026 financial report
- Mercer: Novo Nordisk's GLP-1 list price cut. What to watch next
- ad-hoc-news.de: Novo Nordisk's Wegovy Pill Is Winning the Volume Battle. The 2027 Price Cut Is the War
Spotted an error? Tell us through the contact form; we follow the corrections policy.